Singapore markets closed
Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,921.51 +1,543.03 (+2.36%) CMC Crypto 200
1,369.64 -4.20 (-0.31%)
SANA May 2024 7.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:36PM EDT. Market open.
| Previous close | 0.8800 |
| Open | 1.0000 |
| Bid | 0.4500 |
| Ask | 1.6500 |
| Strike | 7.50 |
| Expiry date | 2024-05-17 |
| Day's range | 1.0000 - 1.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 41 |
Simply Wall St.Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GuruFocus.com
Sana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial Results
Aligns with Analyst Projections Amidst Strategic Clinical Advancements
GlobeNewswireSana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Ongoing ARDENT trial for SC291 continues in B-cell malignancies; expect to report additional data in 2024 Enrolling patients in the ongoing GLEAM trial for SC291 in B-cell mediated autoimmune diseases; expect to report initial clinical data in 2024 Enrolling patients in the ongoing VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expe
© 2024 Yahoo. All rights reserved.